This article is more than 5 years old. Information may no longer be current.
Next-generation robotic PCI system receives FDA clearance
Click Here to Manage Email Alerts
Corindus Vascular Robotics Inc. announced the FDA has cleared for marketing its next-generation system enabling operators to perform PCI robotically.
The system (CorPath GRX) is the newest iteration of the only FDA-cleared device to enable PCI to be performed robotically, which protects medical professionals from exposure to radiation, according to a press release issued by the company.
Novel features contained in the new system include an active guide management system enabling better control of the guide catheter, which enables more precise positioning and may enable the technology to be used in patients with more complex anatomies; and a redesigned bedside unit with an extended reach arm and a touch-screen display for better work flow, the company stated in the release.
“This is a tremendous advancement in the technology platform that will greatly extend clinical capability of the system,” J. Aaron Grantham, MD, chief medical officer of Corindus, said in the release.
The new system is expected to become commercially available in the first quarter of 2017, according to the release.
Disclosure: Grantham is an employee of Corindus.